Comorbidities in COPD: Cardiovascular crossover

Dr Richard Russell is joined this week by Professor David Newby, the Chair of Cardiology at the University of Edinburgh, Scotland, to discuss the overlap between COPD and cardiovascular disease in clinical practice. Listen as they explore the similarities between risk factors and patient presentation, which treatments are the most effective, and how cardiologists and respiratory physicians can work together to be the best for their patients. 1-4 Dr Russell will then highlight an interesting new paper on the associations between COPD and severe pulmonary hypertension,5 before delving into the social media hot topic of the week: mucus in the lungs.

1. Morgan AD, et al. Ther Adv Respir Dis 2018;12:1753465817750524; 2. Rabe KF, et al. Eur Respir Rev 2018;27:180057; 3. Visseren FLJ, et al. Eur Heart J 2021;42:3227–3337; 4. Rogliani P, et al. Int J Chron Obstruct Pulmon Dis 2017;12:3469–3485; 5. Dauriat G, et al. Eur Respir J 2022;60:2102897

Disclosures Professor David Newby Professor Newby reports fees from Amgen (consultancy, research projects), AstraZeneca (meetings, consultancy, lectures, research projects), Boehringer Ingelheim (meetings, lectures, research projects), Bristol Myers Squibb (meetings, consultancy, research projects), British Medical Journal (Deputy Editor of Heart), Cleerly (talks), Elsevier (books), Eli Lilly (meetings, consultancy), GE Healthcare (research projects), GlaxoSmithKline (meetings, consultancy, lectures, trial steering committee, research projects), Roche (research projects), IC Targets (research projects), Inositec (consultancy, research projects), Janssen/Johnson & Johnson (meetings, consultancy, research projects), Life Molecular Imaging (research projects), Medtronic (meetings), Nordic Pharma (research projects), Novartis (consultancy, research projects), Pfizer (meetings, consultancy, lectures, research projects), Sanofi (meetings, consultancy, lectures, research projects), Siemens (research projects), Silence Therapeutics (consultancy), Spacelabs Healthcare (research projects), Toshiba (meetings, consultancy, lectures, research projects), UCB Pharma (consultancy, data monitoring committee), Wyeth (research projects) and Zealand Pharma (consultancy).

Bios:

Professor David Newby Professor David Newby is the British Heart Foundation Duke of Edinburgh Chair of Cardiology at the University of Edinburgh, Director of the Edinburgh Clinical Research Facility, Director of the Edinburgh Imaging Facilities and a Consultant Interventional Cardiologist at the Royal Infirmary of Edinburgh. He has major interests in experimental medicine, advanced imaging and clinical trials in cardiovascular disease. He has investigated the adverse cardiovascular effects of air pollution as well as the interplay between cardiovascular and respiratory disease.

 

This series of podcasts are intended for healthcare professionals only.

The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief.

Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.